[NMusers] RE: R for regulatory use

From: Faelens, Ruben (Belgium) <"Faelens,>
Date: Fri, 23 Mar 2018 15:36:01 +0000

Dear Christina,

I would love to learn a bit more about this, and an open discussion on this=
 list is probably the best way.

Could you elaborate how specifically the open source nature of R causes con=
See the nice documentation from the R project core team at https://www.r-pr=
It seems to me that solid controls are in place, and the self-evaluation of=
 21 CFR part 11 by the R Core team does not result in any cause for concern=
. Perhaps I misinterpret or am too optimistic: Which parts of this self-eva=
luation document would you consider insufficient, or cause for concern?

Also see https://www.r-bloggers.com/r-drug-development-and-the-fda/, https:=
//www.r-bloggers.com/fda-r-ok-for-drug-trials/, and especially presentation=
s/posters from people at FDA: http://user2007.org/program/presentations/sou=
kup.pdf and http://blog.revolutionanalytics.com/downloads/FDA-Janice-Brodsk=
I am quite allergic to people sowing fear, uncertainty and doubt on open-so=
urce software, especially when commercial off-the-shelf software is held to=
 different standards.

Best regards,
Ruben Faelens

From: owner-nmusers_at_globomaxnm.com [mailto:owner-nmusers_at_globomaxnm.com] On=
 Behalf Of Christina Halliday
Sent: vrijdag 23 maart 2018 15:32
To: nmusers_at_globomaxnm.com
Subject: [NMusers] R for regulatory use

Hi Everyone
As we know R has become the programming language of choice in many industri=
es due to its cutting edge capabilities.
However, R's open source nature can cause concern for heavily regulated ind=
ustries and companies that have strict policies around open source usage.
To overcome these concerns, Mango developed "ValidR". Mango's dedicated Val=
idation team have been supporting ValidR customers for a number of years.
ValidR delivers a controlled and validated version of open source R in line=
 with regulatory guidelines such as FDA 21 CFR part 11.

To find out more about ValidR, join our 30-minute free public webinar on Th=
ursday 19 April.
Register for your place here:


Any questions please feel free to contact us at pharma_at_mango-solutions.com<=

Kind regards



This message is intended for the use of the named recipient(s) only and may=
confidential and / or privileged information. If you are not the intended r=
ecipient, please
contact the sender and delete this message. Any unauthorised use of the inf=
contained in this message is prohibited.

Mango Business Solutions Limited is registered in England under No. 4560258=
 with its
registered office at Suite 3, Middlesex House, Rutherford Close, Stevenage,=
 Herts, SG1 2EF,

Information in this email and any attachments is confidential and intended =
solely for the use of the individual(s) to whom it is addressed or otherwis=
e directed. Please note that any views or opinions presented in this email =
are solely those of the author and do not necessarily represent those of th=
e Company. Finally, the recipient should check this email and any attachmen=
ts for the presence of viruses. The Company accepts no liability for any da=
mage caused by any virus transmitted by this email. All SGS services are re=
ndered in accordance with the applicable SGS conditions of service availabl=
e on request and accessible at http://www.sgs.com/en/Terms-and-Conditions.a=

Received on Fri Mar 23 2018 - 11:36:01 EDT

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:58:49 EDT